Clinical Commander

Back to dossier
cardio.atrial_flutter.post-cardiac-surgery.v1PRODUCTION
cardio.atrial_flutter.post-cardiac-surgery.v1

Atrial flutter / atrial tachycardia — post-cardiac-surgery (POAF)

cardiologyacuteadult
Hard-required inputs
0 / 13
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Post-cardiac-surgery AFL/AT (POAF) — incidence 20–70% by surgery type, peak postop day 2–4, multifactorial substrate (pericardial inflammation + sympathetic surge + electrolyte shifts + atrial cannulation injury); usually self-limiting >80% revert by 6–8 wk; route to parent cardio.atrial_flutter.v1 for AC + acute rate management

Inputs
2
Actions
0
Advance rule
Set
Advance when

POAF mechanism + surgery context documented

Patient inputs (15)

Age >75 = higher POAF incidence + higher bleed risk on bridging AC; pediatric post-cardiac-surgery distinct (rare congenital surgery cohort, separate engine)

CABG (20–50% incidence) vs mitral surgery (30–60%) vs MAZE (50–70%) — informs prophylaxis aggressiveness, expected duration, and reversion likelihood; postop day 2–4 = peak window

RVR >130 with hemodynamic compromise → emergent DCCV; HR 100–130 + stable → IV rate control; target HR 80–110 for chronic rate control

Confirms flutter morphology (typical CTI-dependent vs atypical incisional from atriotomy); rules out ischemic substrate from new postop ACS; QTc baseline pre-amiodarone or sotalol

Post-surgical LVEF + LA size + valve status (especially if mitral surgery); EF <40 contraindicates non-DHP CCB; pericardial effusion screen for post-pericardiotomy syndrome

DOAC + amiodarone + metoprolol dose adjustment; bridge LMWH dose adjustment (enoxaparin renal-adjusted CrCl <30); pre-op baseline often available

Cardioplegia + postop diuresis depletes K + Mg → arrhythmogenic substrate; replete K to 4.0–4.5 + Mg to 2.0–2.5 as foundational treatment per AATS 2014 (PMID 24290998)

Post-CABG troponin baseline differentiates POAF-only from POAF + new ischemia; 5x ULN postop is normal range; serial trending if rising

Amiodarone toxicity baseline (TFTs, LFTs) — required pre-amiodarone load especially if planned >4 wk postop course

Hemodynamic stability is the dominant treatment-arm driver: SBP <90 with RVR → emergent DCCV; SBP >90 → IV rate control

Post-pericardiotomy syndrome with effusion / tamponade can present as POAF + hemodynamic compromise; bedside echo to exclude

AC indication + duration: 3 mo time-limited if reverts to sinus and no recurrence vs lifelong if structural substrate

HAS-BLED + recent surgical bleed risk (chest tube output, hematoma, pericardial effusion); drives bridging AC hesitancy in early postop period

PAPABEAR (PMID 15998893) preop amiodarone or COPPS-2 (PMID 25268438) colchicine prophylaxis status — informs prevention success or failure narrative

EXCLUDE LAA thrombus pre-DCCV when AFL persistent >48h and AC not therapeutic ≥3 wk — ACC/AHA 2024 (PMID 38753446); deferred DCCV if thrombus present

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateninghemodynamic_instability_with_rvr_postop
    POAF with RVR + SBP <90 + signs of low cardiac output (cool extremities, oliguria, lactate ≥2) — emergent DCCV indication
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningatrioesophageal_fistula_post_cardioversion_concern
    Late presentation (1-6 wk post-DCCV or post-LA ablation if combined) with fever + chest pain + GI symptoms + neurologic events — suspect atrioesophageal fistula (rare but devastating)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereac_bridging_bleed_risk_postop
    Persistent POAF >48h requiring AC bridge but high bleed risk from chest tube output >200 mL/h, hematoma, or postop coagulopathy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereelectrolyte_derangement_recurrent_postop
    Recurrent K <3.5 or Mg <1.7 despite repletion postop — driving recurrent AFL and limiting rhythm control success
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Post-cardiac-surgery atrial flutter — IV BB rate control + amiodarone rhythm bridge + AC bridge with planned 3-mo duration if reverts; foundational K + Mg repletion + colchicine for post-pericardiotomy co-management — ACC/AHA 2024 (Joglar PMID 38753446); AATS 2014 (Frendl PMID 24290998); STS 2024; COPPS-2 (Imazio PMID 25268438)
axis: post_cardiac_surgery_aflutter_phenotype
Selected axis "Post-cardiac-surgery atrial flutter — IV BB rate control + amiodarone rhythm bridge + AC bridge with planned 3-mo duration if reverts; foundational K + Mg repletion + colchicine for post-pericardiotomy co-management — ACC/AHA 2024 (Joglar PMID 38753446); AATS 2014 (Frendl PMID 24290998); STS 2024; COPPS-2 (Imazio PMID 25268438)" by default fallback (first axis)
  • esmolol
    first line
    beta_blocker_short_acting_iv
    0.5 mg/kg IV bolus over 1 min then 50–300 µg/kg/min infusion; titrate HR 80–110 • IV • continuous; titrate
    triggers: acute_postop_aflutter_with_rvr, hemodynamically_stable_RVR_postop, EF_uncertain_or_reduced
    AATS 2014 first-line short-acting BB for postop RVR; titratable, easily reversible — ideal for evolving postop hemodynamics (PMID 24290998)
    rxcui 203222
  • metoprolol
    first line
    beta_blocker_beta1_selective
    5 mg IV q5 min × 3 doses, then 25–100 mg PO BID • IV/PO • IV bolus then PO BID
    triggers: hemodynamically_stable_RVR_postop, transition_from_esmolol
    AATS 2014 + ACC/AHA 2024 (PMID 38753446) — preferred BB for chronic rate control postop
    rxcui 6918
  • diltiazem
    second line
    non_DHP_CCB
    0.25 mg/kg IV bolus over 2 min then 5–15 mg/h infusion; 120–360 mg PO daily • IV/PO • bolus + infusion or daily PO
    triggers: BB_intolerant_postop, EF_preserved_>50, COPD_with_bronchospasm
    AVN slowing alternative when BB contraindicated; AVOID if EF <40 — ACC/AHA 2024 (PMID 38753446)
    rxcui 3443
  • amiodarone
    first line
    class_III_AAD
    150 mg IV bolus over 10 min then 1 mg/min × 6h then 0.5 mg/min × 18h; 200 mg PO daily × 4–6 wk maintenance • IV/PO • load + daily PO
    triggers: symptomatic_aflutter_stable, rhythm_control_postop, recurrent_aflutter_post_DCCV, POAF_prophylaxis_continuation
    AATS 2014 + STS 2024 + ACC/AHA 2024 (PMID 38753446); pulm/thyroid/LFT monitoring; 4–6 wk taper postop
    rxcui 703
  • colchicine
    add on
    anti_inflammatory_microtubule
    0.5 mg PO BID (≥70 kg) or 0.5 mg PO daily (<70 kg) × 1 mo postop • PO • daily/BID × 1 mo
    triggers: post_pericardiotomy_syndrome, POAF_prevention_postop_first_24h, pericardial_effusion_postop
    COPPS-2 (Imazio JAMA 2014 PMID 25268438) — reduces POAF AND post-pericardiotomy syndrome; SHaPED 2024 colchicine post-CABG extension
    rxcui 2683
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC BID (CrCl >30) or 1 mg/kg SC daily (CrCl 15–30) • SC • BID or daily per CrCl
    triggers: aflutter_persistent_>48h_AC_bridge, transition_to_DOAC_pending, CHA2DS2VASc_>=2
    Bridge AC for persistent POAF >48h; transition to DOAC at 24 h after last LMWH dose — ACC/AHA 2024 (PMID 38753446)
    rxcui 67108
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: CHA2DS2VASc_>=2, persistent_POAF_>48h, planned_3mo_AC_duration
    ARISTOTLE (PMID 21870978) preferred DOAC; 3-mo time-limited if reverts AND no recurrence on follow-up Holter — ACC/AHA 2024 Class I (PMID 38753446)
    rxcui 1364430
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2–3 • PO • daily
    triggers: mechanical_valve_postop, severe_mitral_stenosis, DOAC_contraindicated, severe_renal_failure_CrCl_<15
    Mechanical valve / severe MS / DOAC-ineligible — ACC/AHA 2024 (PMID 38753446)
    rxcui 11289
  • magnesium sulfate
    first line
    electrolyte_anti_arrhythmic
    2 g IV over 15 min then 1–2 g/h titrate Mg 2.0–2.5 • IV • continuous
    triggers: postop_hypomagnesemia, POAF_prevention_foundational, cardioplegia_associated_Mg_depletion
    AATS 2014 (PMID 24290998) — Mg repletion FOUNDATIONAL for POAF prevention and treatment
    rxcui 6585
  • potassium_chloride
    first line
    electrolyte_repletion
    40 mEq IV over 4h or PO 40 mEq q2-4h titrate K 4.0–4.5 • IV/PO • as needed
    triggers: postop_hypokalemia, cardioplegia_associated_K_depletion, diuresis_associated_K_depletion
    AATS 2014 — K target 4.0–4.5 foundational for POAF management
    rxcui 8591

outpatient playbook — drug actions (2)

  1. 1. continue BB long-term if needed
    rxcui 6918
    metoprolol 25-100 mg PO BID • PO • BID
    trigger: rate control + cardioprotection if structural HD
    AATS 2014 + ACC/AHA 2022 HF if EF reduced
  2. 2. continue apixaban indefinitely if structural substrate or recurrent AFL
    rxcui 1364430
    5 mg BID • PO • BID
    trigger: structural substrate or recurrent AFL on Holter
    ACC/AHA 2024 Class I (PMID 38753446)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New atrial flutter on telemetry postoperative day 2–4 after CABG, valve surgery, or MAZE — peak POAF onset window (STS 2024); Atrial flutter with RVR after mitral surgery — incidence 30–60% per LaPar JTCVS 2014; coordinated with cardiac surgery team; Recurrent atrial flutter after surgical MAZE procedure — incidence 50–70% in early postop period; reflects atrial scar substrate plus inflammation.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter / atrial tachycardia — post-cardiac-surgery (POAF)** (cardio.atrial_flutter.post-cardiac-surgery.v1).
Scope: Post-cardiac-surgery AFL/AT (POAF) — incidence 20–70% by surgery type, peak postop day 2–4, multifactorial substrate (pericardial inflammation + sympathetic surge + electrolyte shifts + atrial cannulation injury); usually self-limiting >80% revert by 6–8 wk; route to parent cardio.atrial_flutter.v1 for AC + acute rate management

No severity triggers fired against current inputs.

Plan

Regimen axis: **Post-cardiac-surgery atrial flutter — IV BB rate control + amiodarone rhythm bridge + AC bridge with planned 3-mo duration if reverts; foundational K + Mg repletion + colchicine for post-pericardiotomy co-management — ACC/AHA 2024 (Joglar PMID 38753446); AATS 2014 (Frendl PMID 24290998); STS 2024; COPPS-2 (Imazio PMID 25268438)**.
1. esmolol 0.5 mg/kg IV bolus over 1 min then 50–300 µg/kg/min infusion; titrate HR 80–110 IV continuous; titrate (beta_blocker_short_acting_iv, first line) — AATS 2014 first-line short-acting BB for postop RVR; titratable, easily reversible — ideal for evolving postop hemodynamics (PMID 24290998)
2. metoprolol 5 mg IV q5 min × 3 doses, then 25–100 mg PO BID IV/PO IV bolus then PO BID (beta_blocker_beta1_selective, first line) — AATS 2014 + ACC/AHA 2024 (PMID 38753446) — preferred BB for chronic rate control postop
3. diltiazem 0.25 mg/kg IV bolus over 2 min then 5–15 mg/h infusion; 120–360 mg PO daily IV/PO bolus + infusion or daily PO (non_DHP_CCB, second line) — AVN slowing alternative when BB contraindicated; AVOID if EF <40 — ACC/AHA 2024 (PMID 38753446)
4. amiodarone 150 mg IV bolus over 10 min then 1 mg/min × 6h then 0.5 mg/min × 18h; 200 mg PO daily × 4–6 wk maintenance IV/PO load + daily PO (class_III_AAD, first line) — AATS 2014 + STS 2024 + ACC/AHA 2024 (PMID 38753446); pulm/thyroid/LFT monitoring; 4–6 wk taper postop
5. colchicine 0.5 mg PO BID (≥70 kg) or 0.5 mg PO daily (<70 kg) × 1 mo postop PO daily/BID × 1 mo (anti_inflammatory_microtubule, add on) — COPPS-2 (Imazio JAMA 2014 PMID 25268438) — reduces POAF AND post-pericardiotomy syndrome; SHaPED 2024 colchicine post-CABG extension
6. enoxaparin 1 mg/kg SC BID (CrCl >30) or 1 mg/kg SC daily (CrCl 15–30) SC BID or daily per CrCl (lmwh, first line) — Bridge AC for persistent POAF >48h; transition to DOAC at 24 h after last LMWH dose — ACC/AHA 2024 (PMID 38753446)
7. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — ARISTOTLE (PMID 21870978) preferred DOAC; 3-mo time-limited if reverts AND no recurrence on follow-up Holter — ACC/AHA 2024 Class I (PMID 38753446)
8. warfarin 5 mg daily; INR target 2–3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS / DOAC-ineligible — ACC/AHA 2024 (PMID 38753446)
9. magnesium sulfate 2 g IV over 15 min then 1–2 g/h titrate Mg 2.0–2.5 IV continuous (electrolyte_anti_arrhythmic, first line) — AATS 2014 (PMID 24290998) — Mg repletion FOUNDATIONAL for POAF prevention and treatment
10. potassium_chloride 40 mEq IV over 4h or PO 40 mEq q2-4h titrate K 4.0–4.5 IV/PO as needed (electrolyte_repletion, first line) — AATS 2014 — K target 4.0–4.5 foundational for POAF management

Setting playbook (outpatient) — Long-term cardiology surveillance for AFL recurrence + secondary prevention; lifestyle modification (LEGACY); AC continuation per CHA2DS2-VASc and structural substrate
11. continue BB long-term if needed metoprolol 25-100 mg PO BID PO BID — rate control + cardioprotection if structural HD (AATS 2014 + ACC/AHA 2022 HF if EF reduced)
12. continue apixaban indefinitely if structural substrate or recurrent AFL 5 mg BID PO BID — structural substrate or recurrent AFL on Holter (ACC/AHA 2024 Class I (PMID 38753446))

Non-pharmacologic actions:
- Lifestyle modification (LEGACY PMID 25770315) — alcohol moderation, weight, OSA management
- Cardiac rehab maintenance phase
- AC adherence ongoing

AVOID / contraindication checks:
- Non_DHP_CCB_avoid_EF_below_40 (ACC/AHA 2024 PMID 38753446)
- Beta_blocker_avoid_decompensated_HF_or_severe_bronchospasm (AHA 2022 HF)
- Amiodarone_thyroid_LFT_pulmonary_baseline_required (FDA label)
- DOAC_avoid_mechanical_valve (ACC/AHA 2024)
- LMWH_dose_adjust_CrCl_<30 (FDA label)
- DCCV_defer_if_LAA_thrombus_on_TEE (ACC/AHA 2024)
- Colchicine_avoid_severe_renal_or_hepatic_impairment (FDA label)

Monitoring

Regimen monitoring:
- continuous telemetry x 48-72h post conversion (AATS 2014)
- daily K and Mg with repletion target K 4.0-4.5 Mg 2.0-2.5 (AATS 2014 PMID 24290998)
- QTc q24h on amiodarone or sotalol (FDA label)
- TSH LFT q3-6mo on amiodarone (ACC/AHA 2024)
- CBC q24h during LMWH bridge (HAS-BLED)
- PT/INR at steady state for warfarin (target 2-3)
- chest tube output trend (cardiac surgery protocol)
- bedside echo q24-48h for pericardial effusion (post-pericardiotomy syndrome)
- creatinine q48h during DOAC initiation (KDIGO)
- 30-d Holter for recurrence documentation (ACC/AHA 2024)
- follow-up Holter at 3mo for AC duration decision (ACC/AHA 2024)

Setting (outpatient) monitoring:
- Quarterly BP + weight + symptom score
- Annual ECG + Holter if AC continued

Follow-up plan: Cardiac surgery + cardiology follow-up at 2 wks postop with ECG; cardiology at 4–6 wk for rhythm assessment + AC continuation decision; Holter at 3 mo to document sinus maintenance; AC STOP at 3 mo if reverts AND no recurrence on Holter; cardiac rehab booked; post-pericardiotomy syndrome surveillance with NSAID + colchicine if effusion present
- Close-out criterion: follow-up + Holter + AC duration decision booked

Monitoring phase: Continuous telemetry × 48–72h post-conversion; daily K + Mg with repletion; QTc q24h on amiodarone or sotalol; chest tube output trend; bedside echo q24–48h to monitor effusion; 30-d Holter or implantable loop recorder if persistent

Disposition

Current setting: outpatient — Long-term cardiology surveillance for AFL recurrence + secondary prevention; lifestyle modification (LEGACY); AC continuation per CHA2DS2-VASc and structural substrate

Disposition criteria:
- Long-term cardiology continuation; cross-link to cardio.atrial_flutter.v1 for chronic AFL management or cardio.afib.core.v1 if AF predominant

Escalation triggers (move to higher acuity):
- Recurrent AFL with symptoms → cardiology + EP for ablation consideration (CTI ablation high success)
- New HFrEF → handoff to cardio.hf.core.v1
- Bleeding on AC → cardiology + hematology evaluation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] POAF with RVR + SBP <90 + signs of low cardiac output (cool extremities, oliguria, lactate ≥2) — emergent DCCV indication
- [LIFE_THREATENING] Late presentation (1-6 wk post-DCCV or post-LA ablation if combined) with fever + chest pain + GI symptoms + neurologic events — suspect atrioesophageal fistula (rare but devastating)
- [SEVERE] Persistent POAF >48h requiring AC bridge but high bleed risk from chest tube output >200 mL/h, hematoma, or postop coagulopathy

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar) + AATS 2014 POAF Management Consensus + STS 2024 Post-Cardiac-Surgery AF + COPPS-2 colchicine + ARISTOTLE apixaban [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 24290998) [PMID:24290998](https://pubmed.ncbi.nlm.nih.gov/24290998/)
- Cited evidence (PMID 25268438) [PMID:25268438](https://pubmed.ncbi.nlm.nih.gov/25268438/)
- Cited evidence (PMID 15998893) [PMID:15998893](https://pubmed.ncbi.nlm.nih.gov/15998893/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar) + AATS 2014 POAF Management Consensus + STS 2024 Post-Cardiac-Surgery AF + COPPS-2 colchicine + ARISTOTLE apixaban — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 24290998) — PMID:24290998
  • Cited evidence (PMID 25268438) — PMID:25268438
  • Cited evidence (PMID 15998893) — PMID:15998893